Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Nuvo Research Inc -- Ignore unavailable to you. Want to Upgrade?

To: Ron Nairn who wrote (12698)	7/20/2003 10:11:25 PM
From: axial	Respond to of 14101

Hi, Ron - Thanks for the kind words. "I think now that the patents are secured, the release of good news is considerably more valuable to Dimethaid." I'd like to suggest that the Euro patent news is only part of an effort to secure world-wide expansion of claims in the original Oxo Chemie WF10 patents. While there are a number of patents targeting areas where WF10 has shown efficacy, I have seen none that does what WF10 does - invoke a "macro" response from the immune system. Nor have I seen any whose derivation is from inorganic chemistry, or whose composition is anything like WF10's. I expect we'll see the scope of the patent broadened in the US, Canada, and the rest of the world, too. And yes, you're correct. It would be wise to have all these patents in place (or at least filed) before WF10 becomes widely-known. Regards, Jim